• news.cision.com/
  • Medivir/
  • Medivir AB extends the HIV-protease inhibitor collaboration agreement with Tibotec
English

Medivir AB extends the HIV-protease inhibitor collaboration agreement with Tibotec

Report this content

Medivir AB (OMX Nordic: MVIR B) announced today that their research development and license agreement, in the field of HIV-protease inhibitors, with Tibotec Pharmaceuticals Ltd. is extended for a further year and includes research funding. The programme is presently in preclinical research.

Subscribe

Documents & Links